CN116327873A - Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia - Google Patents
Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia Download PDFInfo
- Publication number
- CN116327873A CN116327873A CN202111583673.0A CN202111583673A CN116327873A CN 116327873 A CN116327873 A CN 116327873A CN 202111583673 A CN202111583673 A CN 202111583673A CN 116327873 A CN116327873 A CN 116327873A
- Authority
- CN
- China
- Prior art keywords
- zedoary turmeric
- turmeric oil
- dry eye
- drug
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000009138 Curcuma zedoaria Species 0.000 title claims abstract description 67
- 235000003405 Curcuma zedoaria Nutrition 0.000 title claims abstract description 62
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 title claims abstract description 62
- 235000019509 white turmeric Nutrition 0.000 title claims abstract description 62
- 239000010681 turmeric oil Substances 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 208000005494 xerophthalmia Diseases 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003889 eye drop Substances 0.000 claims description 36
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 15
- 206010013774 Dry eye Diseases 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 10
- 238000001256 steam distillation Methods 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 7
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 5
- 235000003373 curcuma longa Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 235000013976 turmeric Nutrition 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000004328 sodium tetraborate Substances 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003885 eye ointment Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- -1 pH regulator Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 244000008991 Curcuma longa Species 0.000 claims 2
- 229940100655 ophthalmic gel Drugs 0.000 claims 1
- 229940069265 ophthalmic ointment Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 238000012360 testing method Methods 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000006196 drop Substances 0.000 description 19
- 229940012356 eye drops Drugs 0.000 description 18
- 239000003921 oil Substances 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 9
- 240000000691 Houttuynia cordata Species 0.000 description 8
- 235000013719 Houttuynia cordata Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 238000000465 moulding Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides application of zedoary turmeric oil in preparing a medicine for treating xerophthalmia. Animal pharmacodynamic tests prove that the zedoary turmeric oil has remarkable curative effect on xerophthalmia and can be used for preparing medicines for treating xerophthalmia. The zedoary turmeric oil has small toxic and side effects, no obvious adverse reaction, and has the effects of resisting bacteria and diminishing inflammation, and has great clinical application value.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of zedoary turmeric oil in preparing a medicine for treating xerophthalmia.
Background
Dry eye is currently the most common ocular surface disease affecting vision and quality of life, and has been known by different names such as "office syndrome", "keratoconjunctival dryness", "dry eye" and the like. The incidence rate of domestic xerophthalmia is about 21% -30%, the global prostate is extremely deficient, and only few types of ophthalmic preparations such as artificial tear sodium hyaluronate, cyclosporine eye drops, cyclosporine A ophthalmic emulsion and the like are clinically used at present, so that the potential requirement of new products is high.
With the increasing use time of electronic browsers (mobile phones, computers and the like) for people, patients suffering from xerophthalmia are increased year by year, so that the research on new drugs for treating xerophthalmia with high efficiency and low toxicity has important clinical significance.
Disclosure of Invention
In view of the above, the technical problem to be solved by the invention is to provide an application of zedoary turmeric oil in preparing a medicine for treating xerophthalmia.
The invention provides application of zedoary turmeric oil in preparing a medicine for treating xerophthalmia.
Preferably, the zedoary turmeric oil is used as the only active substance in the medicine for treating xerophthalmia.
Preferably, the zedoary turmeric oil is obtained by steam distillation of zedoary turmeric medicinal materials.
The concentration of the zedoary turmeric oil is preferably 0.5-2 mg/mL, more preferably 1-2 mg/mL, and even more preferably 1mg/mL or 2mg/mL.
Preferably, the zedoary turmeric oil is obtained by extracting zedoary turmeric medicinal materials with carbon dioxide.
The concentration of the zedoary turmeric oil is preferably 0.5-2 mg/mL, more preferably 1-2 mg/mL, and even more preferably 1mg/mL or 2mg/mL.
Preferably, the xerophthalmia is xerophthalmia caused by alkali burn.
The invention provides a medicine for treating xerophthalmia, which comprises zedoary turmeric oil with effective treatment amount and a pharmaceutically acceptable carrier.
Preferably, the medicine for treating xerophthalmia is one or more of eye drops, eye gel and eye ointment.
Preferably, the medicine for treating xerophthalmia comprises:
zedoary turmeric oil, antioxidant, cosolvent, pH regulator, lubricant, osmotic pressure regulator and antiseptic.
Preferably, the medicine for treating xerophthalmia comprises:
zedoary turmeric oil, vitamin E, polysorbate 80, polyethylene glycol, boric acid, borax, sodium chloride and benzalkonium chloride.
Preferably, the medicine for treating xerophthalmia comprises:
preferably, the medicine for treating xerophthalmia is eye drops, which comprises the following components:
compared with the prior art, the invention provides the application of the zedoary turmeric oil in preparing the medicine for treating xerophthalmia. Animal pharmacodynamic tests prove that the zedoary turmeric oil has remarkable curative effect on xerophthalmia and can be used for preparing medicines for treating xerophthalmia. The zedoary turmeric oil has small toxic and side effects, no obvious adverse reaction, and has the effects of resisting bacteria and diminishing inflammation, and has great clinical application value.
Detailed Description
In order to further illustrate the invention, the application of the zedoary turmeric oil provided by the invention in preparing the medicine for treating xerophthalmia is described in detail below with reference to examples.
EXAMPLE 1 preparation of zedoary turmeric oil drop eye
1. Preparation of an oil phase: mixing zedoary turmeric oil, vitamin E, polysorbate 80 and polyethylene glycol 400 to obtain solution 1.
2. Preparation of an aqueous phase: boric acid, borax, sodium chloride and benzalkonium chloride with the prescription amount are dissolved in 200ml of water for injection to obtain solution 2.
3. The aqueous phase was added to the oil phase with stirring, and the mixture was stirred until 1000ml of water for injection was added with stirring.
4. Filtering the prepared solution, sterilizing, and packaging.
Table 1 zedoary turmeric oil drop eye drop prescription
| Material name | Prescription quantity (g) | Use of the same |
| Zedoary turmeric oil | 1.0 | Raw materials |
| Vitamin E | 2.0 | Antioxidant effect |
| Polysorbate 80 | 15.0 | Cosolvent |
| Polyethylene glycol 400 | 4.0 | Cosolvent |
| Boric acid | 11.5 | PH adjustment |
| Borax | 2.0 | Increase transparency and lubrication |
| Sodium chloride | 2.25 | Regulating osmotic pressure |
| Benzalkonium chloride | 0.05 | Preservative agent |
| Injection water is added to | 1000ml |
EXAMPLE 2 research on eye drop drug delivery pharmacodynamics screening experiments of oil drops of Curcumae rhizoma with different concentrations
The improvement effect of the oil drop eye drops of the curcuma zedoary with different extraction processes and different concentrations is examined by using a New Zealand rabbit xerophthalmia model caused by alkali burn, and is compared with the commercially available houttuynia cordata eye drops.
The experiment is divided into 14 groups, namely model control group, herba Houttuyniae eye drop group, bei Fushu eye drop group, curcumae rhizoma oil drop blank matrix group, curcumae rhizoma oil drop eye (steam distillation) 0.125, 0.25, 0.5, 1, 2mg/mL group, and Curcumae rhizoma oil drop eye (CO) 2 Extraction) 0.125, 0.25, 0.5, 1, 2mg/mL groups of 6 animals (6 eyes) each, molding the right eye during experiments, taking the left eye as a control group of the same body, molding, administration and measuring each index according to the set requirements after grouping each test group.
Experimental results:
1) Clinical observations
After molding, the edema and secretion of each molding eye are obviously increased, and gradually decrease along with the prolonged administration time, and basically return to normal except a few animals by the 10 th day of administration. The animals of each test group did not see an abnormal response associated with the test subjects during the test period.
2) Ophthalmic scoring study results
MouldingThe scores of the fluorescein sodium staining and tiger red staining of the posterior model control group, the cordate houttuynia eye drop group, the Bei Fushu eye drop group, the zedoary turmeric oil blank matrix group and the zedoary turmeric oil test groups are close, and no obvious difference (P)>0.05 A) is provided; compared with the model group, on the 4 th day of administration, the cordate houttuynia eye drop group, the Bei Fushu eye drop group, the zedoary turmeric oil blank matrix group and the zedoary turmeric oil test groups have the tiger red dyeing score values close to each other, and no obvious difference is seen (P>0.05). On day 9 of administration, the zedoary turmeric oil blank matrix group score increased with statistical differences (P<0.01 A) is provided; zedoary turmeric oil drop eye drops (CO) 2 Extraction) 2mg/mL fraction score decreased, statistically different (P)<0.05 No significant changes were seen for the other groups.
3) Results of the wet length study of Rabbit eye phenol Red cotton thread
Compared with the negative control eyes, the wetting length of the phenol red cotton threads of the model control group is obviously shorter than that of the negative control eyes on days 1, 5 and 10 of administration, and the statistical difference (P<0.05 or 0.01). Compared with the model control group, the wetting length of phenol red cotton threads of each test group of the houttuynia cordata eye drops, bei Fushu eye drops, zedoary turmeric oil blank matrix group and zedoary turmeric oil are similar on the 1 st day of administration, and no obvious difference is found (P>0.05 A) is provided; compared with the model control group, the herba Houttuyniae eye drop group, bei Fushu eye drop group, and Curcumae rhizoma oil drop (steam distillation) eye drop group, 1, 2mg/mL group, and Curcumae rhizoma oil drop eye drop (CO) 2 Extraction) 0.5, 1 and 2mg/mL group phenol red cotton threads are obviously prolonged in wetting length and have statistical difference (P)<0.05 or 0.01), the blank matrix group of zedoary turmeric oil and other test groups of zedoary turmeric oil have no obvious difference in wetting length of phenol red cotton threads, and no statistical difference (P)>0.05)。
4) Results of study on tear film rupture time in Rabbit
Compared with the negative control eyes, the tear film rupture time of the model control group is obviously shorter than that of the negative control eyes, and the statistical difference (P<0.01). Compared with the model control group, the tear film rupture time of each test group of houttuynia cordata eye drop group, bei Fushu eye drop group, zedoary turmeric oil blank matrix group and zedoary turmeric oil is similar on the 1 st day of administration, and no obvious difference is seen (P>0.05 A) is provided; on day 5 of administration, the houttuynia cordata eye drop group was compared with the model control group0.5, 1, 2mg/mL group of zedoary turmeric oil drop eye liquid (steam distillation), zedoary turmeric oil drop eye liquid (CO) 2 Extraction) tear film rupture time of 0.5, 1 and 2mg/mL groups is obviously prolonged, and statistical difference (P)<0.05 or 0.01), the tear film rupture time of the blank matrix group of zedoary turmeric oil and other test groups of zedoary turmeric oil did not show a significant difference, and no statistical difference (P)>0.05). On day 10 of administration, as compared with the model control group, the houttuynia cordata eye drop group, the Bei Fushu eye drop group, the zedoary turmeric oil drop (steam distillation) 1, 2mg/mL group, the zedoary turmeric oil drop (CO) 2 Extraction) tear film rupture time of 1, 2mg/mL groups is obviously prolonged, and statistical difference (P)<0.05 or 0.01), the tear film rupture time of the blank matrix group of zedoary turmeric oil and other test groups of zedoary turmeric oil did not show a significant difference, and no statistical difference (P)>0.05)。
5) Histopathology
Bei Fushu and herba Houttuyniae eye drops both have an improving effect on conjunctiva, but Bei Fushu has no obvious improving effect on inflammation. The lesion degree of the oil-water vapor extract of the curcuma zedoary with equal concentration is larger than that of CO with equal concentration 2 An extract; the lesion degree of the curcuma zedoary oil-water vapor extract in the groups of 0.5mg/mL, 2mg/mL and 1mg/mL is slightly lighter than that of the other groups. Zedoary turmeric oil CO 2 The lesion degree of the groups of 2mg/mL and 1mg/mL in the extract is slightly lighter than that of the other groups.
The results show that the zedoary turmeric oil drop eye liquid (CO 2 Extraction) 2mg/mL (0.2%), zedoary turmeric oil drop eye liquid (CO) 2 The extracted) 1mg/mL and Bei Fushu eye drops have obvious improvement effect on rabbit xerophthalmia model caused by alkali burn, the effect (0.1 percent) of the extracted eye drops is 2mg/mL (0.2 percent) of the eye drops (steam distillation) of the greater than curcuma zedoary, and the extracted eye drops (steam distillation) of the eye drops is 1mg/mL (0.1 percent) of the eye drops (CO) 2 Extraction) 0.5mg/mL (0.05%) of the congruent zedoary turmeric oil drop eye (steam distillation) 0.5mg/mL (0.05%).
The improvement effect of the curcuma zedoary oil drop eye liquid on the rabbit xerophthalmia model caused by alkali burn is mainly based on improvement of goblet cells and conjunctival epithelial cells, and is not obvious on other improvement effects. The houttuynia cordata eye drops which are the contrast drugs on the market have obvious improving effect on the rabbit xerophthalmia model caused by alkali burn, and the improving effect is also to improve goblet cells and conjunctival epithelial finenessThe cell arrangement is mainly, and has obvious effect of improving inflammation. According to the above research results, zedoary turmeric oil drop eye liquid (CO 2 The extraction) is developed into the eye drops with the optimal concentration of 1-2 mg/mL (0.1% -0.2%), the eye drops can play a better role in dry eye syndrome under the concentration, and the zedoary turmeric oil-water vapor distillation process has an obvious improvement effect in the dry eye syndrome model of alkali burn under the concentration of 1-2 mg/mL (0.1% -0.2%).
The above description of the embodiments is only for aiding in the understanding of the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that various modifications and adaptations of the invention can be made without departing from the principles of the invention and these modifications and adaptations are intended to be within the scope of the invention as defined in the following claims.
Claims (10)
1. The application of zedoary turmeric oil in preparing medicine for treating xerophthalmia is provided.
2. The use according to claim 1, wherein the zedoary turmeric oil is zedoary turmeric oil obtained by steam distillation of zedoary turmeric medicinal material.
3. The use according to claim 1, wherein the zedoary turmeric oil is obtained by carbon dioxide extraction of zedoary turmeric medicinal material.
4. The use according to claim 2 or 3, wherein the concentration of zedoary turmeric oil is 0.5-2 mg/mL.
5. The use according to claim 1, wherein the dry eye is dry eye caused by an alkali burn.
6. A medicament for treating dry eye, comprising a therapeutically effective amount of zedoary turmeric oil and a pharmaceutically acceptable carrier.
7. The drug for treating dry eye according to claim 6, wherein the drug for treating dry eye is one or more of an eye drop, an ophthalmic gel and an ophthalmic ointment.
8. The drug for treating dry eye according to claim 6, wherein the drug for treating dry eye comprises:
zedoary turmeric oil, antioxidant, cosolvent, pH regulator, lubricant, osmotic pressure regulator and antiseptic.
9. The drug for treating dry eye according to claim 8, wherein the drug for treating dry eye comprises:
zedoary turmeric oil, vitamin E, polysorbate 80, polyethylene glycol, boric acid, borax, sodium chloride and benzalkonium chloride.
10. The drug for treating dry eye according to claim 9, wherein the drug for treating dry eye comprises:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111583673.0A CN116327873A (en) | 2021-12-22 | 2021-12-22 | Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111583673.0A CN116327873A (en) | 2021-12-22 | 2021-12-22 | Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116327873A true CN116327873A (en) | 2023-06-27 |
Family
ID=86891679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111583673.0A Pending CN116327873A (en) | 2021-12-22 | 2021-12-22 | Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116327873A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101554369A (en) * | 2008-05-12 | 2009-10-14 | 陈亚玲 | External spraying agent and eye drop of compound oil nano-emulsion as well as preparation method thereof |
| CN101579498A (en) * | 2008-05-14 | 2009-11-18 | 北京和润创新医药科技发展有限公司 | Ready-to-use zedoary turmeric oil ophthalmic gel |
-
2021
- 2021-12-22 CN CN202111583673.0A patent/CN116327873A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101554369A (en) * | 2008-05-12 | 2009-10-14 | 陈亚玲 | External spraying agent and eye drop of compound oil nano-emulsion as well as preparation method thereof |
| CN101579498A (en) * | 2008-05-14 | 2009-11-18 | 北京和润创新医药科技发展有限公司 | Ready-to-use zedoary turmeric oil ophthalmic gel |
Non-Patent Citations (1)
| Title |
|---|
| 张辉等: "莪术油滴眼液治疗单纯疱疹性病毒性角膜炎的临床观察", 《中国医院药学杂志》, vol. 21, no. 08, pages 489 - 490 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2952178B1 (en) | Ophthalmic compositions and methods for treating eyes | |
| CN112190542B (en) | Aqueous in-situ gel ophthalmic preparation for treating xerophthalmia | |
| CN104274601B (en) | A kind of Chinese medicine composition of external curing xerophthalmia and preparation method thereof | |
| DE10161149A1 (en) | Synergistic composition, useful for the treatment of ophthalmological dysfunction, e.g. allergic conjunctivitis, comprises mucopolysaccharide with heparin activity and viscosity regulator, preferably hyaluronic acid | |
| CN110013498A (en) | A kind of eye drops and preparation method thereof of hydrochloric olopatadine | |
| CN104274600B (en) | A kind of new application of Chinese medicine composition | |
| CN105030669B (en) | A kind of curcumin micelle eye drop and preparation method thereof | |
| CN116327873A (en) | Application of zedoary turmeric oil in preparing medicament for treating xerophthalmia | |
| CN111450054B (en) | Ophthalmic preparation containing caffeic acid ester, preparation method and application | |
| CN109125318B (en) | Application of butylphthalide in preparation of medicine for treating xerophthalmia | |
| CN108158983A (en) | A kind of sodium hyaluronate eye drops and preparation method thereof | |
| CN107320446A (en) | A kind of forsythin eye drops and preparation method thereof | |
| CN113368216A (en) | Xerophthalmia treatment preparation and preparation method thereof | |
| CN113786380A (en) | Pilocarpine nitrate ophthalmic gel and preparation method thereof | |
| CN101579357A (en) | Ready-to-use fel ursi ophthalmic gel | |
| CN102512362B (en) | Formula and preparation method of compound ciprofloxacin eye drops | |
| CN115212200B (en) | Puerarin-containing compound preparation for treating diabetic complications and preparation method thereof | |
| CN111905094B (en) | Ophthalmic composition and application thereof in preparation of medicine for treating xerophthalmia | |
| CN101579498A (en) | Ready-to-use zedoary turmeric oil ophthalmic gel | |
| CN103977008A (en) | Dorzolamide and timolol-containing ophthalmic gel and preparation method thereof | |
| CN115708800A (en) | Eye drop composition of sitagliptin and tea polyphenol | |
| CN107260657B (en) | A kind of slow-release forsythin eye drops and preparation method thereof | |
| CN112870216A (en) | Pharmaceutical composition, preparation and application | |
| CN111437252A (en) | Ophthalmic preparation containing erigeron breviscapus extract, preparation method and application | |
| CN116473918A (en) | Brimonidine tartrate eye drops and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |